These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1362267)

  • 41. Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models.
    Gupta D; Radhakrishnan M; Thangaraj D; Kurhe Y
    Eur J Pharmacol; 2014 Jul; 735():59-67. PubMed ID: 24747753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of effects of 5-HT3 antagonists on normal and morphine-attenuated sexual behaviours in female and male rats.
    Tanco SA; Watson NV; Gorzalka BB
    Experientia; 1993 Mar; 49(3):238-41. PubMed ID: 8458409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Behavioural pharmacology of 5-HT3 receptor ligands.
    Barnes JM; Barnes NM; Cooper SJ
    Neurosci Biobehav Rev; 1992; 16(1):107-13. PubMed ID: 1553101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
    Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
    Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
    Hagan RM; Kilpatrick GJ; Tyers MB
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S68-75. PubMed ID: 7831443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of tryptophan residue(s) in the specific binding of agonists/antagonists to 5-HT3 receptors in NG108-15 clonal cells.
    Miquel MC; Emerit MB; Gozlan H; Hamon M
    Biochem Pharmacol; 1991 Sep; 42(7):1453-61. PubMed ID: 1930269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serotonin antagonists induce anxiolytic and anxiogenic-like behavior in zebrafish in a receptor-subtype dependent manner.
    Nowicki M; Tran S; Muraleetharan A; Markovic S; Gerlai R
    Pharmacol Biochem Behav; 2014 Nov; 126():170-80. PubMed ID: 25284132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats.
    Cervo L; Samanin R
    Pharmacol Biochem Behav; 1995 Dec; 52(4):671-6. PubMed ID: 8587903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
    Hamik A; Peroutka SJ
    Cancer Chemother Pharmacol; 1989; 24(5):307-10. PubMed ID: 2527092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 5-HT3 receptors and the neural actions of alcohols: an increasingly exciting topic.
    Lovinger DM
    Neurochem Int; 1999 Aug; 35(2):125-30. PubMed ID: 10405996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The anxiolytic-like effects of 5-hydroxytryptamine3 (5-HT3) receptor antagonists.
    Filip M; Baran L; Siwanowicz J; Chojnacka-Wójcik E; Przegaliński E
    Pol J Pharmacol Pharm; 1992; 44(3):261-9. PubMed ID: 1470564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blockade of accumbens 5-HT3 receptor down-regulation by ondansetron administered during continuous cocaine administration.
    King GR; Xiong Z; Ellinwood EH
    Eur J Pharmacol; 1999 Jan; 364(2-3):79-87. PubMed ID: 9932709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.
    Engleman EA; Rodd ZA; Bell RL; Murphy JM
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):454-67. PubMed ID: 19128203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications.
    Sellers EM; Higgins GA; Tomkins DM; Romach MK; Toneatto T
    J Clin Psychiatry; 1991 Dec; 52 Suppl():49-54. PubMed ID: 1752860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic injection of p-chloroamphetamine eliminates the effect of the 5-HT3 compounds on learning.
    Hong E; Meneses A
    Pharmacol Biochem Behav; 1996 Apr; 53(4):765-9. PubMed ID: 8801576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P.
    Emerit MB; Riad M; Fattaccini CM; Hamon M
    J Neurochem; 1993 Jun; 60(6):2059-67. PubMed ID: 7684066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
    Silverstone PH; Cowen PJ
    Biol Psychiatry; 1994 Sep; 36(5):309-16. PubMed ID: 7993957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.